Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.285 | -9.93031358885 | 2.87 | 3.03 | 2.54 | 5374027 | 2.87129286 | CS |
4 | -0.305 | -10.553633218 | 2.89 | 3.1475 | 2.54 | 2818635 | 2.8968245 | CS |
12 | 0.155 | 6.37860082305 | 2.43 | 3.45 | 2.1 | 2202957 | 2.86404018 | CS |
26 | 0.375 | 16.9683257919 | 2.21 | 3.45 | 1.74 | 2010420 | 2.57729249 | CS |
52 | 0.345 | 15.4017857143 | 2.24 | 3.45 | 1.51 | 1492475 | 2.39742882 | CS |
156 | -17.225 | -86.9510348309 | 19.81 | 22.94 | 1.51 | 951137 | 4.42230229 | CS |
260 | -13.315 | -83.7421383648 | 15.9 | 24.47 | 1.51 | 924317 | 4.94526609 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.